print_label | resize_label

TUDORZA for the long-term maintenance treatment of COPDHow to Use THE INHALER

Reassuring feedback* for your patients The only inhaler that provides reassuring feedback in two ways* each time patients inhale their dose correctly.1 TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy). *Feedback mechanisms consist of visual cues (colored control window) and an audible click.

 
Inhaler Feedback
How to Use Video
Dosing Information
 

Patient feedback in 3 steps1:

  • 1
  • 2
  • 3
TUDORZA PRESSAIR Before Inhalation
1. Ready BEFORE INHALATION
 
  • PRESS and RELEASE the green button
  • READY: Check the colored control window. GREEN means the medicine is ready for inhalation
  • Before you put the inhaler in your mouth, breathe out completely. Do not breathe out into the inhaler. Then place lips tightly around mouthpiece

 
TUDORZA PRESSAIR During Inhalation
2. Click DURING INHALATION
 
  • INHALE quickly and deeply
  • A CLICK sounds during inhalation when inhaler is used correctly
  • Continue inhaling after the click sound to receive full dose

 
TUDORZA PRESSAIR After Inhalation
3. Confirm AFTER INHALATION
 
  • Remove the inhaler from your mouth and hold your breath as long as is comfortable, then breathe out slowly through nose
  • CONFIRM the control window is RED to ensure the full dose has been inhaled correctly
 

For a complete description of how to use the TUDORZA PRESSAIR inhaler, see the Instructions for Use in the full Prescribing Information.

How to Use Video How to Use Video

One inhalation of 400 mcg, twice daily

  • Preloaded with 60 doses for 1 month of treatment1
  • TUDORZA PRESSAIR is a dry powder inhaler (DPI) with a built-in dose indicator1
  • No dosage adjustment necessary for elderly or renally impaired patients1
  • Pregnancy and labor and delivery: use only if the potential benefit to the patient justifies the potential risk to the fetus1
  • Nursing women: exercise caution—excretion in human milk is probable1
TUDORZA PRESSAIR 400 mcg 1 inhalation BID
 

When to discard the PRESSAIR inhaler

TUDORZA PRESSAIR 400 mcg 1 inhalation BID
  • Patients should discard the PRESSAIR inhaler and start a new one when any of the following occurs1:
  • The marking “0” with a red background shows in the middle of the dose indicator

    The device locks out

    45 days after opening the sealed pouch

  • If the inhaler appears damaged or the cap is lost, the inhaler should be replaced1

TUDORZA PRESSAIR is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Expected inspiratory flow rates:

  • The PRESSAIR inhaler delivers the target dose at flow rates as low as 35 L/min1
  • In a study in patients with moderate and severe COPD (n=24 for each), the mean peak inspiratory flow (PIF) was 95.3 L/min (range 54.6-129.4 L/min) and 88.7 L/min (range 72-106.4 L/min), respectively1
  • The amount of drug delivered to the lungs will vary depending on patient factors such as inspiratory flow rate and inspiratory time1

IMPORTANT SAFETY INFORMATION

  • TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy)
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
  • TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively

INDICATIONS AND USAGE

TUDORZA PRESSAIR is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Please also see the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
  
 
 
 

Reference:

  • Prescribing Information for TUDORZA PRESSAIR. AstraZeneca Pharmaceuticals LP, Wilmington, DE.